Ionica Sciences has developed a high sensitivity, precision platform for the detection of infectious diseases in human serum samples. The first test under development is the IonLyme test, a high-sensitivity assay for Lyme disease in humans. Lyme disease, a tick-borne disease, is the fastest growing vector-borne infectious disease in the United States. There is a widely recognized and critical need for better assays to detect Lyme disease in humans. Currently Lyme disease is diagnosed using antibodies, or the body’s response to exposure to Lyme disease. This approach results in poor sensitivity, especially for patients tested within 30 days of infection, since antibody production has not reached detectable levels at that point. Further, new and old infections cannot be differentiated. To address the need for a better Lyme disease diagnostic, Ionica Sciences has combined two existing technologies, DNA aptamers and surface-enhanced Raman scattering (SERS) to create a novel direct test for Lyme disease. In collaboration with FuzeHub, Ionica will purchase a 96-well Raman spectrometer to help transition the IonLyme test from the research laboratory to a clinical reference lab for future sale of the assay to physicians.